Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Invokana Clinical Studies

Credence Logo

Prescribing Information

Great Britain Northern Ireland


Credence Study Endpoints

The CREDENCE trial and its value from a clinical perspective

David Wheeler, Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust looks at the findings of the CREDENCE study and the impact of Invokana on the progression of chronic kidney disease (CKD) and cardiovascular complications in patients with both type 2 diabetes and CKD.

Watch Video
David Wheeler Professor of Kidney Medicine

Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree discusses the CREDENCE study, and how Invokana has emerged as the first treatment to reduce the progression of chronic kidney disease in type 2 diabetes for 20 years.

Watch Video
John Wilding Diabetologist Consultant

Protect T2DM patients against diabetic kidney disease (DKD) progression

In CREDENCE, Invokana + SoC showed a:

30% relative risk reduction in the primary composite outcome compared to placebo + SoC.2

HR: 0.70 (95% CI, 0.57-0.84), p<0.0001.

ARR: 18 fewer events per 1000 patient-years

Doubling of Serum Creatinine

Doubling of Serum Creatinine

Glucose Bottle

End-Stage Kidney Disease

CV Death

CV Death

Kidneys Renal Death

Renal Death

NNT (2.5 yrs)1


Credence Study

Reduce future kidney damage and slow the decline of kidney function

In CREDENCE, Invokana + SoC showed a:

31% reduction in the amount of albuminuria.

Calculated by the geometric mean of the urinary-albumin creatinine ratio compared to placebo + SoC1 (95% CI, 26-35)

Kidney damage

Liquid Container


Reduction in rate of eGFR decline

Invokana reduced the rate of kidney function (eGFR) decline by 60% vs placebo.1

In the chronic phase of the trial (from week 3 until the trial end)3

Difference 2.74/year (95% Cl, 2.37 - 3.11)3


ARR: Absolute Risk Reduction; CI: Confidence Interval; CREDENCE: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; eGFR: estimated Glomerular Filtration Rate; HR: Hazard Ratio; NNT: Number Needed to Treat; RRR: Relative Risk Reduction; SoC: Standard of care; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor.


  • Perkovic V, Jardine M, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/nejmoa1811744.
  • Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: and [Accessed December 2021].
  • Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020;31(5):1128-1139. doi:10.1681/ASN.2019111168.

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or